Xencor, Inc. (NASDAQ:XNCR) Shares Purchased by Sanctuary Advisors LLC

Sanctuary Advisors LLC raised its stake in shares of Xencor, Inc. (NASDAQ:XNCR) by 5.3% in the 4th quarter, HoldingsChannel.com reports. The firm owned 28,263 shares of the biopharmaceutical company’s stock after purchasing an additional 1,432 shares during the quarter. Sanctuary Advisors LLC’s holdings in Xencor were worth $649,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. GAMMA Investing LLC increased its position in Xencor by 31.0% during the fourth quarter. GAMMA Investing LLC now owns 2,147 shares of the biopharmaceutical company’s stock worth $49,000 after purchasing an additional 508 shares during the last quarter. KBC Group NV increased its position in Xencor by 26.0% during the fourth quarter. KBC Group NV now owns 3,936 shares of the biopharmaceutical company’s stock worth $90,000 after purchasing an additional 813 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. increased its position in Xencor by 8.5% during the third quarter. Point72 Asia Singapore Pte. Ltd. now owns 12,156 shares of the biopharmaceutical company’s stock worth $244,000 after purchasing an additional 949 shares during the last quarter. Point72 DIFC Ltd grew its stake in Xencor by 10.9% during the third quarter. Point72 DIFC Ltd now owns 13,511 shares of the biopharmaceutical company’s stock worth $272,000 after buying an additional 1,333 shares during the period. Finally, Yousif Capital Management LLC raised its stake in shares of Xencor by 10.2% in the 4th quarter. Yousif Capital Management LLC now owns 20,976 shares of the biopharmaceutical company’s stock valued at $482,000 after acquiring an additional 1,944 shares during the period.

Analyst Ratings Changes

A number of brokerages have recently commented on XNCR. StockNews.com downgraded shares of Xencor from a “hold” rating to a “sell” rating in a research note on Wednesday. Wedbush reissued an “outperform” rating and issued a $38.00 target price on shares of Xencor in a research note on Thursday, November 7th. Wells Fargo & Company cut their target price on shares of Xencor from $37.00 to $33.00 and set an “overweight” rating on the stock in a research note on Friday. BMO Capital Markets reissued an “outperform” rating and issued a $34.00 target price (up previously from $32.00) on shares of Xencor in a research note on Friday, November 8th. Finally, JPMorgan Chase & Co. raised their target price on shares of Xencor from $27.00 to $28.00 and gave the company an “overweight” rating in a research note on Thursday, November 7th. One equities research analyst has rated the stock with a sell rating, seven have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $34.38.

Xencor Price Performance

XNCR opened at $15.36 on Friday. The company has a fifty day simple moving average of $19.61 and a 200 day simple moving average of $20.64. The firm has a market cap of $1.07 billion, a price-to-earnings ratio of -4.80 and a beta of 0.70. Xencor, Inc. has a twelve month low of $14.18 and a twelve month high of $27.24. The company has a current ratio of 6.23, a quick ratio of 6.23 and a debt-to-equity ratio of 0.01.

Xencor (NASDAQ:XNCR) last released its quarterly earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.62) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.81) by $0.19. The business had revenue of $52.79 million during the quarter, compared to analyst estimates of $17.14 million. Xencor had a negative net margin of 232.77% and a negative return on equity of 30.92%. Equities research analysts expect that Xencor, Inc. will post -3.68 EPS for the current fiscal year.

Insiders Place Their Bets

In other Xencor news, Director Alan Bruce Montgomery sold 1,421 shares of the firm’s stock in a transaction on Wednesday, December 4th. The shares were sold at an average price of $27.03, for a total transaction of $38,409.63. Following the completion of the transaction, the director now directly owns 9,140 shares of the company’s stock, valued at $247,054.20. This trade represents a 13.46 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 5.23% of the stock is owned by company insiders.

Xencor Company Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.